Loxo Oncology trades as part of the biotechnology industry and healthcare sector. Loxo Oncology Inc is a biopharmaceutical company. It is engaged in the development of selective medicines for patients with genetically defined cancers.
SeekingAlpha: Merger Arbitrage Mondays – February 18, 2019
Historical Performance:
Over the last five trading days, LOXO shares returned 0.07% and in the past 30 trading days it returned 67.77%. Over three months, it changed 45.33%. In one year it has changed 149.80% and within that year its 52 week high was 234.93 and its 52 week low was 103.50. LOXO stock is 126.72% above its 52 week low.
Our calculations result in a 200 day moving average of 170.63 and a 50 day moving average of 192.96. Right now, LOXO stock is trading 37.53% above its 200 day moving average.
SeekingAlpha: Merger Arbitrage Mondays – February 18, 2019
Liquidity:
The company has a market cap of $7.2b with 30.8m shares outstanding and a float of 30.3m shares. Trading volume was 400 shares and has experienced an average volume of 1,670,699 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
Earnings:
The last annual reported EPS for Loxo Oncology was -5.18 which ended on 31st of December 2017. Based on 8 analyst estimates, the consensus EPS for the next quarter is -1.16.
Below was the last reported quarterly diluted earnings per share:
| 3rd | Qtr 2018 | Reported 11-08-2018: | -0.89 |
|---|---|---|---|
| 2nd | Qtr 2018 | Reported 08-09-2018: | -0.39 |
| 1st | Qtr 2018 | Reported 05-08-2018: | -0.12 |
| 4th | Qtr 2017 | Reported 03-01-2018: | -0.63 |
| 3rd | Qtr 2017 | Reported 11-02-2017: | -2.45 |
Base on our calculations, the intrinsic value per share is 84.01, which means it might be overvalued by -179.33%.
The long-term trend of the EPS is an important number as it indicates the present value of Loxo Oncology.
Indicators Also to Watch:
Based on the latest filings, there is 138.30% of institutional ownership.
The beta was calculated to be 2.46.
SeekingAlpha: IsoRay EPS in-line, beats on revenue
Fundamental Numbers:
Based on last reported financials, the company’s return on assets is -11.81%, profit margin is -34.29%, price-to-sales is 58.44 and price-to-book is 19.04.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Biotechnology, Healthcare, LOXO, Loxo Oncology
